범유전체 검사 및 다중 유전자 패널 검사(MGPT) 시장 규모, 점유율, 동향 분석 보고서 : 검사별, 적응별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Pan-genomic And Multi-gene Panel Testing Market Summary

The global pan-genomic & multi-gene panel testing market size was estimated at USD 8.96 billion in 2024 and is projected to reach USD 23.19 billion by 2033, growing at a CAGR of 11.37% from 2025 to 2033, driven by driven by clinical adoption in oncology and precision medicine and increasing demand for comprehensive genetic insights, rising use of molecular profiling in treatment planning, and advancements in high-throughput sequencing technologies. Compared to traditional single-gene assays, multi-gene panels that often span dozens to hundreds of cancer-related genes provide deeper and more comprehensive molecular insights.

Clinically validated assays, such as FoundationOne CDx (approximately 324 genes) and MSK-IMPACT (468 genes), are now routinely used in CLIA-certified laboratories to identify actionable genomic alterations. This has improved therapeutic matching, enabling clinicians to identify rare but targetable variants through a single, comprehensive analysis, rather than relying on sequential, time-consuming individual tests. As a result, major cancer centers are incorporating multi-gene and pan-genomic testing into their oncology workflows. Real-world results demonstrate the quantifiable impact of this adoption. A November 2024 study from the American Society of Clinical Oncology (ASCO) found that 36% of patients who underwent pathologist-directed comprehensive genomic profiling (CGP) received a targeted therapy (TT) or immuno-oncology (IO) agent simply because of biomarker findings in their genomic profile.

Moreover, the one of the key factors propelling the growth of the pan-genomic and multi-gene panel testing market is the swift and ongoing decrease in sequencing costs. The National Human Genome Research Institute (NHGRI) reports that significant advancements in next-generation sequencing (NGS) technologies have enabled the cost of sequencing a human genome to decrease from nearly USD 100 million in 2001 to approximately USD 600 in 2024. Comprehensive multi-gene testing was once a specialized and expensive process, but thanks to this significant decrease, it is now a readily available and reasonably priced tool for both patients and diagnostic laboratories. As a result, hereditary cancer testing has shifted from being used primarily in specialized genetics centers to becoming a standard component of preventive care and oncology workflows.

The rising global prevalence of genetic disorders, both inherited and newly occurring, has become one of the strongest drivers of the pan-genomic and multi-gene panel testing market. An estimated 400 million people worldwide suffer from rare genetic disorders, and 3-5% of all newborns are impacted by congenital or inherited genetic conditions. Healthcare systems are quickly incorporating extensive multi-gene and pan-genomic testing into standard protocols for early diagnosis, carrier screening, therapeutic decision-making, and long-term disease management as the genetic basis of more diseases becomes more apparent. Adoption in oncology is being greatly increased by the growing recognition of hereditary cancer syndromes, such as Lynch syndrome, Li-Fraumeni syndrome, and BRCA-associated breast/ovarian cancer. With 5-10% of all cancers classified as hereditary, and BRCA1/2 mutations increasing breast cancer risk by up to 70% and ovarian cancer risk by up to 40%, the need for proactive and comprehensive genomic screening has never been more compelling.

In addition, the increasing complexity of genomic data, particularly from whole-genome and large multi-gene panel tests, poses a significant challenge because interpreting millions of variants necessitates extensive clinical genomics and bioinformatics expertise. Many laboratories struggle to find enough molecular geneticists, clinical geneticists, and bioinformaticians to handle the workload. According to a global adoption framework for NGS in oncology published in PMC, a shortage of well-trained personnel, such as clinical molecular geneticists and genomic analysts, impedes widespread implementation. Moreover, infrastructural gaps in sequencing and bioinformatics pipelines exacerbate the issue, making it difficult to maintain consistent quality across laboratories.

Global Pan-genomic And Multi-gene Panel Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pan-genomic & multi-gene panel testing market report based on test, application, end-use, and region:

• Test Outlook (Revenue, USD Million, 2021 - 2033)
• Pan-Genomic / Whole Exome Based Panels
• Comprehensive Hereditary Disease Panels
• Oncology Multi-Gene Panels
• Pharmacogenomics (PGx) Panels
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Cardiology & Cardiomyopathy
• Neurology and Neurogenetics
• Rare & Undiagnosed Genetic Diseases
• Reproductive Carrier Screening
• Newborn & Pediatric Genomics
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital-based Genetic Labs
• Independent Diagnostic Labs
• Specialty Genomic Centers
• Others
• Regional Outlook (USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Pan-Genomic & Multi-Gene Panel Testing Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Test
    • 1.1.1.2. Application Segment
    • 1.1.1.3. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Pan-Genomic & Multi-Gene Panel Testing Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Test
• 2.3. Application Snapshot
• 2.4. End Use Snapshot
• 2.5. Competitive Landscape Snapshot

Chapter 3. Pan-Genomic & Multi-Gene Panel Testing Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Clinical adoption in oncology and precision medicine
  • 3.4.2. Falling sequencing costs & tech advances
  • 3.4.3. Increasing burden of genetic disorders & rising
• 3.5. Market Restraint Analysis
  • 3.5.1. Complexity of data interpretation & shortage of skilled genomic specialists
  • 3.5.2. Regulatory challenges, compliance Burdens & lack of standardization
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Pan-Genomic & Multi-Gene Panel Testing Market: Test Estimates & Trend Analysis

• 4.1. Pan-Genomic & Multi-Gene Panel Testing Market: Test Movement Analysis
• 4.2. Pan-Genomic / Whole Exome Based Panels
  • 4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.3. Comprehensive Hereditary Disease Panels
  • 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Oncology Multi-Gene Panels
  • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Pharmacogenomics (PGx) Panels
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Pan-Genomic & Multi-Gene Panel Testing Market: Application Estimates & Trend Analysis

• 5.1. Pan-Genomic & Multi-Gene Panel Testing Market: Application Movement Analysis
• 5.2. Oncology
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.3. Cardiology & Cardiomyopathy
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Neurology and Neurogenetics
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Rare & Undiagnosed Genetic Diseases
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Reproductive Carrier Screening
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Newborn & Pediatric Genomics
  • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Pan-Genomic & Multi-Gene Panel Testing Market: End Use Estimates & Trend Analysis

• 6.1. Pan-Genomic & Multi-Gene Panel Testing Market: End Use Movement Analysis
• 6.2. Hospital-based Genetic Labs
  • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.3. Independent Diagnostic Labs
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Specialty Genomic Centers
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Others
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Pan-Genomic & Multi-Gene Panel Testing Market: Regional Business Analysis

• 7.1. Regional Market Snapshot
• 7.2. North America
  • 7.2.1. North America Pan-Genomic & Multi-Gene Panel Testing Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.2.2.2. Key Country Dynamics
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. Reimbursement Scenario
    • 7.2.2.5. Competitive Scenario
  • 7.2.3. Canada
    • 7.2.3.1. Canada Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.2.3.2. Key Country Dynamics
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Reimbursement Scenario
    • 7.2.3.5. Competitive Scenario
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.2.4.2. Key Country Dynamics
    • 7.2.4.3. Regulatory Framework
    • 7.2.4.4. Reimbursement Scenario
    • 7.2.4.5. Competitive Scenario
• 7.3. Europe
  • 7.3.1. Europe Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.3.2.2. Key Country Dynamics
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. Reimbursement Scenario
    • 7.3.2.5. Competitive Scenario
  • 7.3.3. Germany
    • 7.3.3.1. Germany Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.3.3.2. Key Country Dynamics
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Reimbursement Scenario
    • 7.3.3.5. Competitive Scenario
  • 7.3.4. Spain
    • 7.3.4.1. Spain Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.3.4.2. Key Country Dynamics
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Reimbursement Scenario
    • 7.3.4.5. Competitive Scenario
  • 7.3.5. France
    • 7.3.5.1. France Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.3.5.2. Key Country Dynamics
    • 7.3.5.3. Regulatory Framework
    • 7.3.5.4. Reimbursement Scenario
    • 7.3.5.5. Competitive Scenario
  • 7.3.6. Italy
    • 7.3.6.1. Italy Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.3.6.2. Key Country Dynamics
    • 7.3.6.3. Regulatory Framework
    • 7.3.6.4. Reimbursement Scenario
    • 7.3.6.5. Competitive Scenario
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.3.7.2. Key Country Dynamics
    • 7.3.7.3. Regulatory Framework
    • 7.3.7.4. Reimbursement Scenario
    • 7.3.7.5. Competitive Scenario
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.3.8.2. Key Country Dynamics
    • 7.3.8.3. Regulatory Framework
    • 7.3.8.4. Reimbursement Scenario
    • 7.3.8.5. Competitive Scenario
  • 7.3.9. Norway
    • 7.3.9.1. Norway Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.3.9.2. Key Country Dynamics
    • 7.3.9.3. Regulatory Framework
    • 7.3.9.4. Reimbursement Scenario
    • 7.3.9.5. Competitive Scenario
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Japan Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.4.2.2. Key Country Dynamics
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Scenario
    • 7.4.2.5. Competitive Scenario
  • 7.4.3. China
    • 7.4.3.1. China Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.4.3.2. Key Country Dynamics
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Scenario
    • 7.4.3.5. Competitive Scenario
  • 7.4.4. India
    • 7.4.4.1. India Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.4.4.2. Key Country Dynamics
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Scenario
    • 7.4.4.5. Competitive Scenario
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.4.5.2. Key Country Dynamics
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Reimbursement Scenario
    • 7.4.5.5. Competitive Scenario
  • 7.4.6. Thailand
    • 7.4.6.1. Thailand Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.4.6.2. Key Country Dynamics
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Reimbursement Scenario
    • 7.4.6.5. Competitive Scenario
  • 7.4.7. Australia
    • 7.4.7.1. Australia Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.4.7.2. Key Country Dynamics
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Reimbursement Scenario
    • 7.4.7.5. Competitive Scenario
• 7.5. Latin America
  • 7.5.1. Latin America Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.5.2.2. Key Country Dynamics
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Scenario
    • 7.5.2.5. Competitive Scenario
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.5.3.2. Key Country Dynamics
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Scenario
    • 7.5.3.5. Competitive Scenario
• 7.6. MEA
  • 7.6.1. MEA Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. South Africa Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.6.2.2. Key Country Dynamics
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Scenario
    • 7.6.2.5. Competitive Scenario
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Saudi Arabia Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.6.3.2. Key Country Dynamics
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Scenario
    • 7.6.3.5. Competitive Scenario
  • 7.6.4. UAE
    • 7.6.4.1. UAE Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.6.4.2. Key Country Dynamics
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Scenario
    • 7.6.4.5. Competitive Scenario
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.6.5.2. Key Country Dynamics
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Scenario
    • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
  • 8.2.1. New Product Launch
  • 8.2.2. Partnerships
  • 8.2.3. Acquisition
  • 8.2.4. Collaboration
  • 8.2.5. Funding
• 8.3. Key Company Market Share Analysis, 2024
• 8.4. Company Heat Map Analysis
• 8.5. Company Profiles
  • 8.5.1. Illumina, Inc.
    • 8.5.1.1. Company Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Thermo Fisher Scientific, Inc.
    • 8.5.2.1. Company Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Fulgent Genetics
    • 8.5.3.1. Company Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Ambry Genetics (Tempus)
    • 8.5.4.1. Company Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. GeneDx
    • 8.5.5.1. Company Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Baylor Genetics
    • 8.5.6.1. Company Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Natera
    • 8.5.7.1. Company Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Caris Life Sciences
    • 8.5.8.1. Company Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Foundation Medicine, Inc. (Roche)
    • 8.5.9.1. Company Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Guardant Health
    • 8.5.10.1. Company Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives